Kenvue Inc.
Financials
Valuation Metrics
Kenvue Inc.'s Market Cap is $37.08B. At end of 2025 it was $32.68B. Ranked #393 of 3,116 in US market (top 13%), #282 of 1,644 on NYSE (top 17%), #5 of 17 in Household & Personal Products (top 29%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $37.08B | US#393/3,116 Sec#5/17 |
| Revenue | $15.41B | US#409/3,116 Sec#5/17 |
| Net Income | $1.66B | US#385/3,116 Sec#5/17 |
| Total Assets | $26.73B | US#520/3,116 Sec#3/17 |
| Net Assets | $10.55B | US#403/3,116 Sec#3/17 |
| Employees | 21,780 | US#524/3,116 Sec#7/17 |
| Value | ||
| P/E | 22.34x | US#1,261/3,116 Sec#5/17 |
| P/B | 3.51x | US#1,926/3,116 Sec#8/17 |
| PEG | 1.32x | US#920/3,116 Sec#3/17 |
| P/S | 2.40x | US#1,477/3,116 Sec#10/17 |
| EV/EBITDA | 14.04x | US#1,392/3,116 Sec#7/17 |
| FCF Yield | 5.71% | US#1,252/3,116 Sec#7/17 |
| Profitability | ||
| ROE | 15.71% | US#835/3,116 Sec#6/17 |
| ROA | 6.20% | US#889/3,116 Sec#8/17 |
| Op. Margin | 19.52% | US#921/3,116 Sec#5/17 |
| Revenue Growth | 1.76% | US#2,055/3,116 Sec#7/17 |
| Earnings Growth | 16.93% | US#907/3,116 Sec#3/17 |
| Financial Health | ||
| Debt Ratio | 153.34% | US#1,519/3,116 Sec#9/17 |
| Total Debt | $8.48B | US#469/3,116 Sec#4/17 |
| FCF | $2.12B | US#339/3,116 Sec#5/17 |
| Cash | $1.11B | US#622/3,116 Sec#5/17 |
| Current Ratio | 1.01x | US#2,270/3,116 Sec#12/17 |
| Net Debt/EBITDA | 2.33x | US#1,432/3,116 Sec#9/17 |
| Dividend | ||
| Div. Yield | 6.42% | US#188/3,116 Sec#1/17 |
| Div. Growth | -89.71% | US—/3,116 Sec—/17 |
| Performance | ||
| 1Y Return | 38.89% | US#680/3,116 Sec#4/17 |
| 1M Return | 9.34% | US#804/3,116 Sec#6/17 |
| From 52W High | -4.07% | US#283/3,116 Sec#2/17 |
| 1Y MDD | -13.26% | US#163/3,116 Sec#1/17 |
| Trading | ||
| Volume | 66,596,317 shares | US#137/3,116 Sec#1/17 |
| Trading Value | $1.31B | US#498/3,116 Sec#7/17 |
| Per Share | ||
| EPS | $0.86 | US#1,708/3,116 Sec#10/17 |
| BPS | $5.50 | US#2,232/3,116 Sec#13/17 |
Company Info
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.